WTG
PLRX icon

West Tower Group’s Pliant Therapeutics PLRX Stock Holding History

West Tower Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,701
Closed -$85.1K – 409
2023
Q4 		$85.1K Buy
+4,701
New +$71.5K 0.17% 90

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

West Tower Group's PLRX Position: Q1 2024 in Review

West Tower Group sold out of Pliant Therapeutics (PLRX) in Q1 2024, closing a stake of 4,701 shares — an estimated $85.1K sold.

West Tower Group first reported a position in PLRX in Q4 2023 and held it in 1 quarter. The position peaked at $85.1K in Q4 2023. 135 funds tracked by Wall St. Rank hold PLRX as of Q1 2024.

  • West Tower Group reported no remaining Pliant Therapeutics position as of Q1 2024 after selling out during the quarter.
  • West Tower Group sold 4,701 Pliant Therapeutics shares in Q1 2024, an estimated $85.1K.
  • West Tower Group first reported a position in Pliant Therapeutics in Q4 2023 and held it in 1 quarter.
  • West Tower Group's Pliant Therapeutics position peaked at $85.1K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2024.

Based on West Tower Group's 13F filing for Q1 2024, filed 14 May 2024.